{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.54","value":"24.99"},{"groupId":"OG001","spread":"17.28","value":"31.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"description":"CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumour cells. Results are reported for combined Part 2 and 3.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 2 and 3 Combined: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 2 and 3 Combined: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg"}],"paramType":"MEAN","populationDescription":"Safety population included all the participants who received at least one dose of study treatment. Here, \"Number of participants analyzed\" signifies number of evaluable participants for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Part 2 and 3: Week 1 end of infusion (EOI)","title":"Part 2 and 3 Combined: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells","type":"SECONDARY","unitOfMeasure":"Percentage of Cells"}